Company intelligence / Profile preview

Micrographia Bio

London, England, United Kingdommicrographiabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

No published clinical results. The company’s main achievement to date appears to be development and validation (including pilot partnerships) of its spatial proteomics/AI drug discovery platform. Seven pilot partnerships cited as validating the technology's utility in mapping compound activities inside human cells.

Modalities: small moleculesbiologics
Industry: Drug Discovery Services

Partnerships

Seven unnamed pilot partners referenced validating their approachInvestors include Stevenage Bioscience Catalyst, Tech Nation Applied AI, Entrepreneur First

Beyond the preview

Go deeper on Micrographia Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micrographia Bio.

Explore the full profile